8 March 2019 | Outerspace Melbourne has settled in the new makerspace in Abbotsford, a short drive from the old studio. The team enjoyed designing the “clean slate” space and making it their own, with an open layout…
Read More8 March 2019 | Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European…
Read More8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…
Read More8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…
Read More